MDA

Registration Opens for MDA Summer Camp for Children with Neuromuscular Diseases

Retrieved on: 
Tuesday, January 17, 2023
IAFF, Safeway, Citgo, Muscular Dystrophy Association, MDA, Community engagement, Degenerative disease, Transformer, Randalls, Acosta Sales & Marketing, Neuromuscular disease, General Motors, Thumb, Summer camp, Magic, Creativity, Muscular dystrophy, Research, Volunteering, Counselor, Life, ALS, Albertsons, NALC, Tourism, Genentech

New York, NY, Jan. 17, 2023 (GLOBE NEWSWIRE) -- The Muscular Dystrophy Association (MDA) announced today the opening of registration for its MDA Summer Camp program for children ages 8 to 17 living with muscular dystrophy and related neuromuscular diseases.

Key Points: 
  • New York, NY, Jan. 17, 2023 (GLOBE NEWSWIRE) -- The Muscular Dystrophy Association (MDA) announced today the opening of registration for its MDA Summer Camp program for children ages 8 to 17 living with muscular dystrophy and related neuromuscular diseases.
  • MDA Summer Camp provides opportunities for children and teens with neuromuscular diseases to participate in enriching recreational experiences that promote independence and self-confidence while developing critical skills and forging lifelong friendships.
  • MDA has been providing summer camp for children with neuromuscular diseases for nearly 70 years, at no cost to families.
  • In 2023 MDA will offer 24 one-week in-person summer camp sessions June 4 through August 25, as well as virtual camp options, at no cost to families.

Muscular Dystrophy Association Awards Venture Philanthropy Funding to PathMaker Neurosystems to Develop Neuromodulation Treatment for ALS

Retrieved on: 
Tuesday, January 17, 2023
Venture philanthropy, Neurodegeneration, Entrepreneurship, MVP, Muscular Dystrophy Association, Doctor of Philosophy, Biomedical engineering, MDA, Motor neuron, Amyotrophic lateral sclerosis, Degenerative disease, Muscular dystrophy, CERF, EFS, ALS, NIH, Pharmaceutical industry

BOSTON and NEW YORK, Jan. 17, 2023 (GLOBE NEWSWIRE) -- The Muscular Dystrophy Association (MDA) and PathMaker Neurosystems Inc. (“PathMaker”), a near-commercial stage neuromodulation company developing breakthrough non-invasive systems for the treatment of serious neurological disorders, announced today an investment of $600,000 through the MDA Venture Philanthropy (MVP) program to PathMaker to advance its work in amyotrophic lateral sclerosis (ALS).

Key Points: 
  • BOSTON and NEW YORK, Jan. 17, 2023 (GLOBE NEWSWIRE) -- The Muscular Dystrophy Association (MDA) and PathMaker Neurosystems Inc. (“PathMaker”), a near-commercial stage neuromodulation company developing breakthrough non-invasive systems for the treatment of serious neurological disorders, announced today an investment of $600,000 through the MDA Venture Philanthropy (MVP) program to PathMaker to advance its work in amyotrophic lateral sclerosis (ALS).
  • MDA uses the Venture Philanthropy program to invest in companies committed to clinical application of high-impact, novel treatments for neuromuscular diseases, including ALS.
  • This funding will support the launch of an ALS early feasibility study (EFS) using PathMaker’s breakthrough technology for motor neuron hyperexcitability suppression.
  • To learn more about the Muscular Dystrophy Association and the MVP program, please visit https://www.mda.org/science/mda-venture-philanthropy .

FDA’s Peter Marks, M.D., Ph.D. to deliver Keynote Address at 2023 Muscular Dystrophy Association Clinical & Scientific Conference

Retrieved on: 
Tuesday, January 10, 2023
Blood, Muscular Dystrophy Association, Doctor of Philosophy, MDA, China Biologic Products, Degenerative disease, Hilton Anatole, Keynote, Safety, Muscular dystrophy, FDA, Neuromuscular disease, Vaccine, Drug development, Conference, Food, Episcopal conference, Center for Biologics Evaluation and Research, Public policy, US Foods, Human, Medical device, Pharmaceutical industry, Research

New York, NY, Jan. 10, 2023 (GLOBE NEWSWIRE) -- The Muscular Dystrophy Association (MDA) today announced Peter Marks, M.D., Ph.D. as the Keynote Speaker at the MDA 2023 Clinical & Scientific Conference.

Key Points: 
  • New York, NY, Jan. 10, 2023 (GLOBE NEWSWIRE) -- The Muscular Dystrophy Association (MDA) today announced Peter Marks, M.D., Ph.D. as the Keynote Speaker at the MDA 2023 Clinical & Scientific Conference.
  • Registration for the global convening of the worldwide neuromuscular disease community is open for both in-person and virtual registration here .
  • “It’s my privilege to be a part of this important global gathering convened by the Muscular Dystrophy Association.
  • “We are honored to have Dr. Marks speak at our 2023 Clinical & Scientific Conference,” said Sharon Hesterlee, Ph.D., Chief Research Officer, MDA.

Muscular Dystrophy Association Elects Governor Brad Henry as Chairman and Christopher Rosa, Ph.D. as Vice Chairman of the Board of Directors

Retrieved on: 
Monday, January 9, 2023
Wall Street, University, Education, Muscular Dystrophy Association, MDA, Heart, Harvard Law Review, Viscardi Center, Myopathy, Muscular dystrophy, Senate, Law review, Hope, Organization, Economics, University of Oklahoma College of Law, Social mobility, Patient, Executive Committee, III, 2021 Oklahoma State Senate special election, Disability, Success, Management

New York, NY, Jan. 09, 2023 (GLOBE NEWSWIRE) -- The Muscular Dystrophy Association (MDA) announced today the election of new Board of Directors leadership .

Key Points: 
  • New York, NY, Jan. 09, 2023 (GLOBE NEWSWIRE) -- The Muscular Dystrophy Association (MDA) announced today the election of new Board of Directors leadership .
  • Governor Brad Henry will now serve as Chairman of the Board of Directors of MDA and Christopher Rosa, Ph.D. will serve as the Vice Chairman.
  • Governor Henry has been a committed and dedicated Board member for over a decade, and Dr. Rosa, has been a devoted member of the Board for decades.
  • "We are very pleased to share that both Governor Brad Henry and Dr. Chris Rosa have accepted their new positions on the Board of Directors of the Muscular Dystrophy Association," said Donald S. Wood, Ph.D., President and CEO, MDA.

Entrada Therapeutics Announces Clinical Candidate, ENTR-601-45, for the Potential Treatment of People Living with Duchenne Muscular Dystrophy who are Exon 45 Skipping Amenable

Retrieved on: 
Monday, January 9, 2023
IND, Muscular Dystrophy Association, Therapy, MDA, RNA transfection, Duchenne muscular dystrophy, EEV, Entrada, Conference, DMD, Exon, Patient, Episcopal conference, Investigational New Drug, PMO, Pharmaceutical industry, Duchenne

The Company plans to submit an Investigational New Drug (IND) application in the second half of 2024.

Key Points: 
  • The Company plans to submit an Investigational New Drug (IND) application in the second half of 2024.
  • “There is a profound unmet need for people living with Duchenne and the more than 1,300 people in the US and Europe who are exon 45 skipping amenable,” said Dipal Doshi, President and Chief Executive Officer of Entrada Therapeutics.
  • Entrada plans to present additional data in support of ENTR-601-45 at the Muscular Dystrophy Association (MDA) Clinical & Scientific Conference in March 2023.
  • ENTR-601-45 is designed to address the underlying cause of Duchenne muscular dystrophy due to mutated or missing exons in the DMD gene.

Global Missiles and Missile Defense Systems Market Report 2023: Featuring BAE, Lockheed Martin, Northrop Grumman, L3Harris & More

Retrieved on: 
Monday, January 9, 2023
Government, Terrorism, Partnership, Missile defense, United Nations Industrial Development Organization, Weapon, DRDO, Government agency, Private sector, Growth, ICBM, Bomber, Investment, Defence Research and Development Organisation, VL-SRSAM, Unmanned aerial vehicle, Standard, RIM-161 Standard Missile 3, Missile, MDA, Intelligence, Jet fuel

DUBLIN, Jan. 9, 2023 /PRNewswire/ -- The "Global Missiles and Missile Defense Systems Market Size, Segments, Outlook, and Revenue Forecast 2022-2028 by Range, Missile Type, Missile Defense system and Region" report has been added to ResearchAndMarkets.com's offering.

Key Points: 
  • DUBLIN, Jan. 9, 2023 /PRNewswire/ -- The "Global Missiles and Missile Defense Systems Market Size, Segments, Outlook, and Revenue Forecast 2022-2028 by Range, Missile Type, Missile Defense system and Region" report has been added to ResearchAndMarkets.com's offering.
  • According to this analysis, the Global Missiles and Missile Defense Systems Market was valued at ~US$ 20 billion in 2017.
  • The market for Missiles and Missile Defense Systems will be driven by government spending on missiles and missile defense systems across national land and water borders is being driven by rising military budgets in response to rising geopolitical tensions among various countries and fears about terrorism..
  • Anti-aircraft missiles are guided weapons intended to harm or kill airplanes and include surface-to-air missiles, air-to-air missiles, and subsurface-to-air missiles
    By Missile Defence system - The Surface-To-Surface Missiles segment accounted for the highest market share in 2021 in the global missile and missile defense system market.

Canadian Cannabis; Down but Far from Out - Growth for 2023 and Beyond

Retrieved on: 
Thursday, December 22, 2022
Statistics Canada, Legislation, Rotation, OTC Markets Group, High Tide, Health Canada, AZ Business Magazine, News, THC, Growth, Stock, CBD, Orbital, The Motley Fool, Genetics, Cannabis, MDA, Drug, Oil, Crossfade

While growth in the Canadian market hasn't been as aggressive as expected, we are still seeing overall growth from the previous year.

Key Points: 
  • While growth in the Canadian market hasn't been as aggressive as expected, we are still seeing overall growth from the previous year.
  • In 2022, total sales have increased 18.4% compared to the first ten months of 2021 to C$3.72 billion.
  • A standard cultivation license is necessary for larger companies that want to build and grow in a large-scale facility.
  • With a recovery perhaps on the way, I would consider getting in on cannabis stocks before 2023 is out."

EQS-News: SREP capital requirements for Commerzbank remain unchanged for 2023

Retrieved on: 
Sunday, January 22, 2023
Pillar, Commerzbank, European Central Bank, Risk, Common equity, Central bank, AT1, MDA, Bank

In the annual Supervisory Review and Evaluation Process (SREP) the European Central Bank has confirmed that the bank-specific capital requirements for the Commerzbank Group remain unchanged for 2023.

Key Points: 
  • In the annual Supervisory Review and Evaluation Process (SREP) the European Central Bank has confirmed that the bank-specific capital requirements for the Commerzbank Group remain unchanged for 2023.
  • The additional own funds requirement for Pillar 2 (P2R) still stands at 2% of total capital, thereof at least 1.125% have to be covered with Common Equity Tier 1 (CET1) capital.
  • The SREP decision replaces the previous SREP decision with effect from 1 January 2023.
  • As of 30 September 2022, the pro forma CET1 requirement for Commerzbank on group level stands unchanged at 9.44% of risk weighted assets (MDA threshold) when applying the new SREP decision.

SREP capital requirements for Commerzbank remain unchanged for 2023

Retrieved on: 
Sunday, January 22, 2023
Pillar, Commerzbank, European Central Bank, Risk, Common equity, Central bank, AT1, MDA, Bank

Bettina Orlopp: "With a 13.8% CET-1 rate as of 30 September 2022, we have a comfortable buffer to the MDA threshold."

Key Points: 
  • Bettina Orlopp: "With a 13.8% CET-1 rate as of 30 September 2022, we have a comfortable buffer to the MDA threshold."
  • In the annual Supervisory Review and Evaluation Process (SREP) the European Central Bank has confirmed that the bank-specific capital requirements for the Commerzbank Group remain unchanged for 2023.
  • The SREP decision replaces the previous SREP decision with effect from 1 January 2023.
  • As of 30 September 2022, the pro forma CET1 requirement for Commerzbank on group level stands unchanged at 9.44% of risk weighted assets (MDA threshold) when applying the new SREP decision.

Kratos Rocket Systems Supports Multiple Successful Ballistic Missile Intercept Tests During Japan Flight Test Aegis Weapon System-07 Event

Retrieved on: 
Tuesday, December 27, 2022
National security, Government, ICEX: US Navy Mission in Arctic, Pacific Ocean, JMSDF, PMRF, Research, JS Haguro, Aegis, Kratos Defense & Security Solutions, SAN, Pacific Missile Range Facility, JS Maya, Oriole, M270 Multiple Launch Rocket System, SRBM, DDG, MRBM, Standard, RIM-161 Standard Missile 3, United States Navy, MDA, Jet fuel, Kratos

The intercept was the highlight of the Japan Flight Test Aegis Weapon System-07 (JFTM-07) event which featured four Kratos subscale ballistic missile targets that was conducted by the Japan Maritime Self-Defense Force (JMSDF) and the United States Missile Defense Agency (MDA) over a span of two weeks from the Pacific Missile Range Facility (PMRF) in Hawaii.

Key Points: 
  • The intercept was the highlight of the Japan Flight Test Aegis Weapon System-07 (JFTM-07) event which featured four Kratos subscale ballistic missile targets that was conducted by the Japan Maritime Self-Defense Force (JMSDF) and the United States Missile Defense Agency (MDA) over a span of two weeks from the Pacific Missile Range Facility (PMRF) in Hawaii.
  • During the event, the Kratos team also supported a live-fire event featuring the engagement of a short-range ballistic missile (SRBM) target by the JS Haguro (DDG 180).
  • Kratos is a leading provider of products, solutions, and services supporting ballistic missile defense for Aegis, hypersonic testing, atmospheric science research and technology maturation.
  • “Our team works side-by-side with our government customers to deliver transformative and affordable target systems and vehicles from mission inception through successful launch operations.